

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Franks et al.

Application No. 10/009,376

Filed: December 3, 2001

For: GENE THERAPY PRODUCTS


Examiner: Not yet assigned

Date: March 14, 2002

Art Unit: Not yet assigned

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on March 14, 2002 as First Class Mail in an envelope addressed to: BOX PCT, COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

  
Agent for Applicant

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(b)(3)


BOX PCT  
COMMISSIONER FOR PATENTS  
WASHINGTON, DC 20231

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this Information Disclosure Statement, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this Information Disclosure Statement is enclosed.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By:   
Susan Alpert Siegel, Ph.D.  
Registration No. 43,121

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

**INFORMATION DISCLOSURE  
STATEMENT**
**BY APPLICANT**

Docket: 5585-61760

App: 10/009,376

Applicant: Franks et al.

Filed: 12/3/2001

Art Unit: Not yet assigned

**U.S. PATENT DOCUMENTS**

Init.*		Number	Date	Name	Class	Sub	Filed
		6,037,329	14 Mar 00	Baird			

**FOREIGN PATENT DOCUMENTS**

		Number	Date	Country	Class	Sub		
		WO 91/01004	24 Jan. 1991	PCT				
		WO 92/20364	26 Nov. 1992	PCT				
		WO 93/06847	15 Apr. 1993	PCT				
		WO 93/17038	2 Sep. 1993	PCT				
		WO 95/27732	19 Oct. 1995	PCT				
		WO 99/26660	3 Jun. 1999	PCT				
		0 158 198	23 Mar. 1985	EP				
		0 318 948	30 Nov. 1988	EP				
		0 398 305	16 May 1990	EP				
		0 510 949	22 Apr. 1992	EP				
		0 624 377	13 May 1994	EP				
		WO 95/24928	21 Sep 95	WIPO				
		WO 95/28494	26 Oct 95	WIPO				
		WO 96/06641	07 Mar 96	WIPO				
		WO 96/08274	21 Mar 96	WIPO				

EXAMINER:

DATE

\*Examiner: Initial if considered, whether or not in conformance with MPEP 60;  
draw line through cite if not in conformance and not considered. Send copy.

<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>BY APPLICANT</b>				Docket: 5585-61760		App: 10/009,376	
				Applicant: Franks et al.			
				Filed: 12/3/2001		Art Unit: Not yet assigned	
P		WO 96/36362	21 Nov 96	WIPO			
X		WO 99/07324	18 Feb 99	WIPO			
P		WO 00/07543	17 Feb 00	WIPO			
X		WO 00/40269	13 Jul 00	WIPO			
X		224885	10 Mar 87	Europe			
X		259863	16 Mar 88	Europe			
X		475230	18 Mar 92	Europe			
X		510949	28 Oct 92	Europe			
X		2000184897	04 Jul 00	Japan			
<b>OTHER DOCUMENTS</b>							
			Ogata M. et al., (1989) <i>Proc. Nat'l Acad. Sci. USA</i> <b>86</b> , 4215-4219				
			Sutherland F. et al., (1990) <i>Cancer Immunol. Immunother.</i> <b>31</b> , 312-320				
			Le Maistre C.F. et al., (1991) <i>Lancet</i> <b>337</b> , 1124-1125				
			Cristiano & Curiel, (1996) <i>Cancer Gene Therapy</i> <b>3</b> , 49-57				
			Cristiano & Roth, (1996) <i>Cancer Gene Therapy</i> <b>3</b> , 4-10				

EXAMINER:	DATE
*Examiner: Initial if considered, whether or not in conformance with MPEP 60; draw line through cite if not in conformance and not considered. Send copy.	

**INFORMATION DISCLOSURE  
STATEMENT**

**BY APPLICANT**

Docket: 5585-61760

App: 10/009,376

Applicant: Franks et al.

Filed: 12/3/2001

Art Unit: Not yet assigned

Matos da Silva A.C. et al., (1996) *Am. J. Health-Syst. Pharm.* **53**, 1722-1727

Bukowski R.M., (1997) *Cancer* **80**, 1198-1220

Konigsberg P.J. et al., (1998) *Biochem. Biophys. Acta* **1370**(2), 243-251

Proleukin prescribing information (Chiron Corporation, January 1998)

Sundin D.J. et al., (1998) *Am. J. Health-Syst. Pharm.* **55**, 1520-1523

Alemanly et al., *Cancer Gene Therapy*, Vol. 3, No. 5, pp. 296-301 (1996)

Baird et al., *J. Endocrinol. Abstract Supplement*, Vol. 164, S8 (2000)

Brunner et al., *Gene Therapy*, Vol. 7, pp. 401-407 (2000)

Palyi et al., *Proc. Natl. Acad. Sci. USA*, Vol. 96, pp. 2361-2366 (1999)

Sosnowski et al., *J. Biol. Chem.*, Vol. 271, No. 52, pp. 33647-33653 (1996)

EXAMINER:

DATE

\*Examiner: Initial if considered, whether or not in conformance with MPEP 60;  
draw line through cite if not in conformance and not considered. Send copy.